Key Points
- William Jacob Savage, an insider at Disc Medicine, sold 7,378 shares on March 2 at an average price of $65.88 for a total of $486,062.64, cutting his stake to 85,211 shares (about $5.61M) — a 7.97% reduction.
- Savage has been selling repeatedly in recent months, including 3,256 shares on Feb. 17 (avg $62.86) and 13,093 shares on Dec. 15 (avg $91.22), signaling sustained insider selling activity.
- Disc Medicine stock was trading around $61.10 with a $2.31B market cap and negative P/E; analysts collectively rate it a "Moderate Buy" with an average target of $104.80 despite several recent price-target cuts.
Disc Medicine, Inc. (NASDAQ:IRON - Get Free Report) insider William Jacob Savage sold 7,378 shares of the company's stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $65.88, for a total transaction of $486,062.64. Following the completion of the sale, the insider directly owned 85,211 shares in the company, valued at approximately $5,613,700.68. The trade was a 7.97% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
William Jacob Savage also recently made the following trade(s):
- On Tuesday, February 17th, William Jacob Savage sold 3,256 shares of Disc Medicine stock. The shares were sold at an average price of $62.86, for a total value of $204,672.16.
- On Monday, December 15th, William Jacob Savage sold 13,093 shares of Disc Medicine stock. The stock was sold at an average price of $91.22, for a total value of $1,194,343.46.
Disc Medicine Stock Performance
Disc Medicine stock remained flat at $61.10 during midday trading on Thursday. The company had a trading volume of 27,865 shares, compared to its average volume of 728,833. The stock's fifty day simple moving average is $73.48 and its two-hundred day simple moving average is $75.59. The company has a debt-to-equity ratio of 0.04, a current ratio of 21.94 and a quick ratio of 23.45. The company has a market cap of $2.31 billion, a price-to-earnings ratio of -10.20 and a beta of 0.87. Disc Medicine, Inc. has a 12-month low of $30.82 and a 12-month high of $99.50.
Disc Medicine (NASDAQ:IRON - Get Free Report) last announced its quarterly earnings results on Thursday, February 26th. The company reported ($1.62) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.69) by $0.07. The company had revenue of ($19.88) million during the quarter, compared to analyst estimates of $0.15 million. As a group, equities analysts expect that Disc Medicine, Inc. will post -4.07 earnings per share for the current year.
Wall Street Analyst Weigh In
IRON has been the topic of several analyst reports. Cantor Fitzgerald dropped their price target on shares of Disc Medicine from $153.00 to $125.00 and set an "overweight" rating on the stock in a research report on Tuesday, February 17th. Weiss Ratings reissued a "sell (d-)" rating on shares of Disc Medicine in a research note on Wednesday, January 21st. Wedbush dropped their target price on Disc Medicine from $110.00 to $88.00 and set an "outperform" rating on the stock in a research report on Tuesday, February 17th. BMO Capital Markets cut their price target on Disc Medicine from $120.00 to $100.00 and set an "outperform" rating for the company in a research note on Tuesday, February 17th. Finally, TD Cowen reiterated a "buy" rating on shares of Disc Medicine in a research report on Friday, December 19th. Ten investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $104.80.
Check Out Our Latest Research Report on Disc Medicine
Institutional Trading of Disc Medicine
Institutional investors have recently modified their holdings of the stock. RA Capital Management L.P. increased its stake in shares of Disc Medicine by 25.3% during the fourth quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company's stock worth $156,925,000 after purchasing an additional 399,026 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Disc Medicine by 22.1% in the 4th quarter. Vanguard Group Inc. now owns 1,767,680 shares of the company's stock worth $140,371,000 after buying an additional 319,621 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in Disc Medicine by 28.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,698,005 shares of the company's stock worth $134,839,000 after buying an additional 371,576 shares in the last quarter. JPMorgan Chase & Co. increased its stake in Disc Medicine by 110.0% during the 4th quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company's stock worth $125,557,000 after buying an additional 828,248 shares in the last quarter. Finally, Wellington Management Group LLP raised its holdings in shares of Disc Medicine by 7.7% during the fourth quarter. Wellington Management Group LLP now owns 1,518,274 shares of the company's stock valued at $120,566,000 after acquiring an additional 108,197 shares during the last quarter. Institutional investors and hedge funds own 83.70% of the company's stock.
Disc Medicine Company Profile
(
Get Free Report)
Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.
The company's pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
